The 10,000 ft.² Woodlands site is located near Houston in Texas and is going to design, develop, and even manufacture research-grade plasmid DNA – pDNA materials in order to support the work of the CDMO within cell and gene therapy.
Bionova Scientific, which is the subsidiary of global conglomerate Asahi Kasei, is going to expand its biologics through its new facility, which would offer beyond the mammalian protein production and also see that it is able to offer clinical- to commercial-scale Current good manufacturing practice (CGMP) production when it comes to pDNA by the fourth quarter of 2025.
Apparently, plasmid DNA happens to be the starting material for a number of advanced therapeutics, which includes the likes of mRNA as well as cell and gene therapies, which are viral vector-based.
The president and chair of Bionova Scientific, Darren Head, remarked that for new US pDNA development facility they chose the Woodlands due to the fact of its proximity to a growing number of CGT companies and its location, which offers Bionova the access to expand the CGT ecosystem within the US in a rapid way.
